Abstract | Erectile dysfunction is a prevalent condition that leads to significant morbidity and distress, not just for affected men but also for their partners. Very few currently available treatments ameliorate the underlying causes of the disorder and 'cure' the disease state. Much recent effort has been focused on the development of gene and cell-based approaches to rectify the molecular and tissue defects responsible for ED. Gene therapy has been investigated in animal models as a means to restore normal function to the penis; at this time, however, only one human trial has been published in the peer-reviewed literature. Recent gene therapy studies have focused on the modulation of enzymes associated with the NOS/cGMP pathway, and supplementation of trophic factors, peptides and potassium channels. Stem cell therapy has been a topic of interest in more recent years but there are currently very few published reports in animal models and none in human men. Although stem cell therapy offers the potential for restoration of functional tissues, legitimate concerns remain regarding the long-term fate of stem cells. The long-term safety of both gene and stem cell therapy must be thoroughly investigated before large-scale human studies can be considered.
Introduction
erectile dysfunction (eD) is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. 1 this troublesome condition can affect men at any age, although it is more common in older men; estimates of eD prevalence are generally less than 10% in men younger than 40 years but the rate increases to almost 30% in men in their 50s and over 50% in men older than 60 years.
1,2 eD can be caused by pathological alteration in the anatomy of the penile vasculature, impairment of the neurovascular processes mediating penile vasodilation, alterations of the normal testosterone milieu, or psychogenic disturbances. 3 existing medical treatment modalities for eD (such as phosphodiesterase type 5 inhibitors, intracavernous vasodilatory agents, and vacuum tumescence devices) are focused on the short-term modification of hemodynamic factors to facilitate penile engorgement. 4 although effective, these treatments carry the risk of adverse effects and can be burdensome for men and their partners who desire sexuality to be spontaneous. the only treatments that have been definitively proven to permanently reverse the pathological changes associated with eD are testo sterone supplementation in cases of severe hypo gonadism, and arterial bypass in the rare case of isolated arterial injury. while these modalities are of use in some situations, they cannot reverse the gradual decline in erectile capacity associated with tissue senescence. a treatment to restore the normal function of the penile neurovasculature would be a boon to the management of eD and has been the topic of intensive research around the world.
Gene therapy and stem cell therapy are exciting new methods that offer the potential to reverse the underlying causes of eD and thus reduce patient reliance on medical erectogenic agents. in this review we provide an overview of the current status of both gene and stem cell therapy for the management of eD, and highlight recent studies that suggest combining gene and stem cell therapy might give optimal results.
Pathogenesis of ED
the primary biochemical pathway underlying the process of penile erection is thought to be the nitric oxide synthase (nos)/cGmP cascade. 5 there has been intense interest in exploring the relationship between conditions associated with eD, such as aging, diabetes, hypercholesterolemia, and cavernous nerve injury, and the nos/cGmP signal transduction pathway in animal model systems.
aging is associated with elevated vasoconstrictor tone and decreased relaxation of the corpora cavernosa mediated by both endothelial and neurogenic means. 6 this is presumably owing to inadequate activation of neuronal nos (nnos) and subsequently reduced production of nitric oxide (no). 7 Decreased no bioavailability impairs vasodilation and enhances formation of reactive oxygen species (ros) that can cause tissue damage. 8, 9 Diabetes contributes to eD via neuropathic damage to cavernous nerves, increased oxidative stress, altered angiogenesis, dyslipidemia, endothelial dysfunction, and perturbation of nos metabolism. [10] [11] [12] Hypercholesterolemia is thought to cause impairment of no mediated endothelium-dependent relaxation in the smooth muscle cells of the corpus cavernosum. 13 Cavernous nerve injury interrupts no release from nitrergic nerve terminals in the cavernosal arteries and corporal bodies, which inhibits erectile capacity. Furthermore, denervation of the corporal bodies after cavernous nerve injury has been associated with smooth muscle and collagen changes that are likely to exacerbate the condition.
Gene therapy
Gene therapy is the replacement or upregulation of genes intended to ameliorate a tissue defect or damage.
14 one of the principle challenges of gene therapy is the development of mechanisms to deliver Dna into the cells of interest. a number of vector systems exist, each with associated advantages and disadvantages (table 1) .
naked plasmid Dna can be safely delivered directly into cells but has low transfection efficiency in most cell types. 15 adenoviral vectors are easy to construct and 18 Hsv vectors lack multiple essential gene functions, and have a unique promoter system that remains active during latency, allowing expression of therapeutic proteins without compromising the latent viral state. Hsv vectors also have the capacity for high-affinity uptake by nerve termini, allowing efficient delivery of viral Dna to nerve cell bodies without chromo somal integration.
14 Dna can also be complexed to liposomal constructs for transfection, although this is not very efficient in most cell types. 19 Gene therapy has also been performed via ex vivo gene transfection of cultured mesenchymal cells that are later reintroduced into the host organism; this limits the potential for expression of transgenes in nontarget cells. 20, 21 a nonviral polyethylenimine gene delivery system has been utilized that avoids the risks of viral vectors and allows for continuous expression of genes over a longer period with minimal amount of Dna injected. However, nonspecific interactions of these polymer complexes with other tissues and blood might hamper their efficacy in some cases. 22, 23 in addition to vector selection, tissue specific promoters and enhancers can improve the efficacy of gene therapy and potentially minimize adverse effects. 15 the external positioning, limited blood flow, and slow cellular turnover of the penis make it an ideal target for gene therapy. 24 the risk of systemic adverse effects from penile administration of a gene is thought to be minimal. 25 Furthermore, the presence of gap junctions allows the corporal tissue to act as a syncytium, permitting the nonselective exchange between cells of numerous physiologically relevant intracellular second messengers and ions. thus, gene delivery to only a few cells might have profound effects on neighboring cells. 26, 27 Given the relatively small number of cells that need to be transfected for efficacy in management of eD, naked plasmid Dna was the vector of choice for the only human study of gene therapy for eD performed thus far. 26 alternative viral vectors have been utilized in numerous animal studies that are summarized in the following sections, organized according to the target gene of interest.
Enzymes no is a potent vasodilator that is generated by the metabolism of arginine by the enzyme nos.
28,29 the release of no activates no-sensitive guanylyl cyclase in vascular tissues, such as the penis. this increases penile tissue cGmP levels, leading to downstream molecular actions that cause penile erection. 30 Decline in penile no synthesis in cavernous nerve terminals and the penile endothelium is a very common cause of eD. 31, 32 restoration of endogenous no synthesis or potentiation of the downstream effectors of no (such as cGmP) is therefore of Nitric oxide synthase nnos and endothelial nos (enos) are the principal nos isoforms involved in the induction of penile erection. 33 ,34 a third isoform (inducible nos; inos), which might also play a role in penile erection, has a distinctive expression pattern and demonstrates Ca 2+ dependence. 35 Gene transfer of enos and inos for treatment of eD has been studied in animal models. transfer of the enos gene via adenoviral vector in streptozotocin (stZ)-induced diabetic rats is associated with increased cavernous tissue enos activity and no biosynthesis 1-2 days after treatment. Furthermore, rats treated with the adenoviral construct demonstrated penile hemodynamics (mediated by cavernous nerve stimulation) similar to those observed in animals not exposed to stZ, implying restoration of normal erectile function in these animals. 32 Combined enos adenoviral gene transfer and intravenous sildenafil in stZ-induced diabetic rats results in a greater synergistic erectile response than observed with either therapy alone. 36 intracavernous administration of syngeneic mesenchymal stem cells (msCs) transfected with enos ex vivo improves endothelium-derived no biosynthesis and neurogenic-mediated erectile responses in the aged rat at 7 and 21 days after injection. this response is probably mediated by msC differentiation into new endothelial and smooth muscle cells. interestingly, administration of unmodified msCs led to improvements in penile hemodynamics at 21 days but not at 7 days, 37 suggesting that gene therapy intervention causes a more rapid improvement in penile hemodynamics.
Plasmid Dna transfer of inos has been demonstrated to enhance nos activity and improve penile hemo dynamics in aged rats, as determined by cavernous nerve electrostimulation at 4, 10 and 21 days after treatment. 31 transfection of the inos gene with plasmid vectors, adeno viral vectors, or adenovirus-transduced rEViEWS myoblast cells has also been explored in healthy adult rats; myoblast-mediated transfer produced a robust retention of inos activity in the cavernosa and this was associated with superior erectile response to cavernous nerve stimula tion at 2, 4 and 7 days after treatment. lower levels of inos retention were noted in animals treated with adenoviral or plasmid vectors. 20 cGMP-dependent protein kinase G1 cGmP-dependent protein kinase G1 (PKG1) is the target by which cGmP induces vasodilation in corporal tissue. Deficiency of PKG1 has been shown to impair no induced vasodilation in animal models. 38 PKG1 is downregulated in experimentally induced diabetic rabbits and rats. 39, 40 adenoviral-mediated transfer of the PKG1α gene into the corpora cavernosa of these rats restored total PKG1 activity to the levels observed in control rats. these molecular changes were associated with physiologically relevant enhancement of penile hemo dynamics during cavernous nerve electrostimulation 2 days after transfer. 40 Heme oxygenase Carbon monoxide has vasodilatory properties similar to no, probably owing to activation of guanylate cyclase. 41, 42 Heme oxygenase catalyzes the rate-limiting step in the oxidative degradation of heme to produce biliverdin and carbon monoxide. upregulation of Ho1 activity in aged rats using a cDna liposome complex resulted in increased Ho enzyme activity and cGmP level up to 1 week after treatment. 19 Superoxide dismutase elevation of serum glucose (as occurs in diabetic states) leads to the production of reactive oxygen species that induce oxidative stress. 43 reactive oxygen species react with no, reducing its bioavailability and leading to eD. [44] [45] [46] extracellular superoxide dismutase reduces the concentration of reactive oxygen species. intracavernous adenoviral delivery of the extracellular superoxide dismutase gene into rats with stZ-induced diabetes results in reduced levels of reactive oxygen species, increased cavernosal cGmP expression, and improved erectile hemodynamics during cavernous nerve electrostimulation at 2 days after treatment. 46 Protein inhibitor of NOS the protein inhibitor of nos (Pin) has been detected in the rat major pelvic ganglion and inhibits nnos activity by blocking dimerization. 47 antisense rna and short hairpin rna (shrna) plasmid constructs inhibit translation and induce degradation of Pin mrna, thus silencing Pin gene expression. 48 intracavernosal injection of plasmids encoding antisense Pin rna or Pin shrna enhances erectile response to cavernous nerve electrical field stimulation 1 month after injection. 49 Both shrna and antisense constructs improve penile hemo dynamics during cavernous nerve electrostimulation in aged rats; shrna was slightly more efficacious at increasing intracavernous pressure (iCP). 50 Arginase increased arginase activity results in a depleted level of arginine available for no biosynthesis in the penis. 51 arginase expression is higher in the cavernous tissues of humans and animals with diabetes than in nondiabetic controls; inhibition of this enzyme has been demonstrated to facilitate corporal smooth muscle relaxa tion. 52, 53 Gene transfer of antisense arginase in an adeno viral vector leads to decreased arginase i protein and mrna levels in the penile tissues of aged mice. these changes are associated with increased cGmP production and improved erections on cavernous nerve stimulation in vivo 1 month after transfer. 54 RhoA the rhoa/rho kinase pathway is upregulated in the penile tissues of rabbits with experimentally induced diabetes, 55 and is thought to relate to diabetes-associated eD. transfer of a dominant negative mutant gene of rhoa (designed to inhibit rhoa activity) was demonstrated to reduce rhoa/rho kinase phosphorylation in rats with stZ-induced diabetes; improvements in erectile response to cavernous nerve electrostimulation were also observed 7 days after treatment. 56 growth factors the use of gene delivery techniques that enhance sustained focal release of trophic factors theoretically provides a more durable means of supplying these factors than administration of a single or even multiple doses after physiological insult, although not all research to date has supported this theory. 57 neuronal regeneration strategies have been of particular interest in animal models of cavernous nerve injury (table 3) .
Neurotrophic growth factors
Glial cell line-derived neurotrophic factor (GDnF) promotes survival and extension of sympathetic and parasympathetic axons. 58 GDnF and its receptors are expressed in penile parasympathetic and sensory neurons and are involved in the survival and regenera tion of these structures. 59, 60 Fluoro-Gold ™ labeled GDnF in an Hsv vector can enhance erectile function in cavernous nerve injured rats, resulting in signifi cantly improved iCP response to cavernous nerve electrostimulation 4 weeks after treatment.
an increase in Fluoro-Gold ™ labeled cells was detected in the major pelvic ganglion of Hsv-GDnF treated animals, indicating retrograde transport of the vector to the major pelvic ganglion and suggesting enhanced nerve regeneration and survival in response to this treatment. 14 neurturin is a member of the GDnF family that has been shown to enhance survival and regeneration of postganglionic neurons innervating the penis in a more specific fashion than GDnF. [61] [62] [63] rats treated with Hsvneurturin after cavernous nerve injury were shown to have higher mean iCP:aP (arterial pressure) ratios 4 weeks after treatment than injured rats that received Hsv-vector alone or no treatment. retrograde tracing studies revealed a significant improvement in nerve integrity in the neurturin treatment group. 63 rEViEWS neurotrophin 3 promotes growth, differentiation and survival of sensory and motor neurons and might be protective against mechanical and metabolic insults. 64 it has been shown to induce neurite fiber outgrowth in cultured major pelvic ganglion. 65 in rats with stZ-induced diabetes, cavernous injection of neurotrophin 3 in a viral vector caused a significant increase in iCP:aP ratio when compared to control animals at 4 weeks after treatment. 66 Furthermore, the number of nnos-positive neurons in the major pelvic ganglion was significantly increased in the neurotrophin 3 group.
Brain-derived neurotrophic factor (BDnF) has been shown to enhance nerve growth after cavernous nerve injury. 67 Gene transfer of BDnF using an adenoviral vector was evaluated in a rat model of cavernous nerve injury at 4 and 8 weeks after treatment. superior iCP results during cavernous nerve electrostimulation were observed in the treatment group, as well as enhanced staining for nnos and naDPH. 68 these effects have been confirmed in a rat model of hypercholesterolemia; BDnF was shown to preserve neuronal content as well as erectogenic response to cavernous nerve stimulation and administration of intracavernous papaverine 4 months after gene transfer. treated rats also manifested higher smooth muscle content relative to controls. 69 Insulin-like growth factor I insulin-like growth factor i (iGF-i) plays a key role in regeneration of nos-expressing neurons after caver nous neurotomy or cryoinjury in rats.
70,71 Downregulation of iGF-i protein expression has been detected in penile tissues of diabetic rats. 72 Cavernosal gene transfer of iGF-i using an adenoviral vector in stZ-induced diabetic rats was shown to increase cavernous expression of iGF-i mrna and protein, and improve iCP response to cavernous nerve electrostimulation relative to untreated controls 1-2 days after treatment. 73 Vascular endothelial growth factor vascular endothelial growth factor (veGF) is a potent mitogen known to improve erectile function in several animal models of eD, including hypercholesterolemic a nonviral polyethylenimine gene delivery system has been used to transfect a veGF gene into the corpora cavernosa of stZ-induced diabetic rats; treated animals demon strated increased smooth muscle content of the corporal tissue 3 weeks after gene transfer, as well as improved iCP on electrostimulation, relative to controls. 22 Corporal injection of a veGF gene via an adeno viral vector has been shown to enhance angiogenesis, enos phosphorylation, and cGmP expression in a hyper cholesterolemic rat model for eD at 7, 14 and 56 days. this effect was enhanced by concomitant transfer of the angiopoietin 1 gene, which counteracts veGF-induced inflammation in endothelial cells. 76 iCP after cavernous nerve electrostimulation was similar between nonhyper cholesterolemic animals and hyper cholesterolemic animals that received combined angiopoietin 1 and veGF treatment, whereas intra cavernous injection of either molecule alone elicited partial non significant improvement in iCP. 76 intracorporal treatment with adenoviral associ ated veGF has also been shown to prevent castration associated erectile impairment in rats. However, gene transfer was less efficacious than direct injection with veGF protein. 57 Peptides and potassium channels a number of peptides are known to have modulatory effects on smooth muscle tone and consequently might be exploited to potentiate penile erection in eD (table 4) . vasoactive intestinal peptide (viP) is a potent vaso dilator that acts by stimulation of adenylate cyclase and appears to be a mediator of penile erection. [77] [78] [79] in an stZ-induced diabetic rat model of eD, intracorporal injection of viP led to sustained expression of the gene. upregulation of viP was maintained for 14 days and was associated with a significant increase in iCP compared to untreated control animals. 80 Calcitonin gene related peptide (CGrP) is a potent vasodilator that exerts its effects by increasing intracellular camP and reducing intracellular Ca 2+ , thus contributing to smooth muscle relaxation in the penis. 81, 82 Direct injection of an adenovirus encoding the preproCGrP gene into the penis of aged rats caused increased levels of CGrP protein, mrna, and camP in cavernosal tissue. these changes were associated with higher iCP on cavernosal nerve stimulation than untreated controls 5 days after treatment. 83 Potassium channels have an important role in the modula tion of cellular hyperpolarization and relaxation, and hence smooth muscle tone.
3,84 overexpression of potassium channels in corporal smooth muscle cells is thought to increase their sensitivity to various neurotransmitters. the relaxation response of the atPsensitive potassium channel K atP (atP-sensitive inward rectifier potassium channel 11) is impaired in corporal tissue strips taken from men with diabetes, and this probably contributes to eD. 85 transfer of the K atP gene to the penis of aged rats results in increased cavernosal levels of K atP mrna and enhanced iCP during cavernous nerve electrostimulation. 86 Cellular large-conductance Ca 2+ -activated potassium channels, such as BK channels, are activated by no/ Abbreviations: CGRP , calcitonin gene related peptide; ED, erectile dysfunction; ICP , intracavernous pressure; IIEF-EF, international index of erectile function-erectile function domain; K ATP , ATP-sensitive inward rectifier potassium channel 11; MaxiK, calcium-activated potassium channel subunit alpha-1; NA, not applicable; STZ, streptozotocin; VIP , vasoactive intestinal peptide.
rEViEWS cGmP-mediated mechanisms, leading to cellular hyperpolarization. 87, 88 Hyperpolarization of smooth muscle cell membranes prevents calcium influx and facilitates muscle relaxation and vasodilation. suppression or knockout of BK channels tends to enhance corporal smooth muscle contractions. 89, 90 Corporal smooth muscle transfection of KCNMB1 cDna (commonly referred to as hSlo), which encodes the human smooth muscle calcium-activated potassium channel subunit alpha-1 (maxiK), was performed in 9 month old rats. KCNMB1 Dna was incorporated into corporal smooth muscle cells and expressed for at least 2 months; Dna incorporation was associated with enhanced iCP during cavernous nerve electrostimulation. 91 in a follow-up study, it was demon strated that KCNMB1 cDna transfer was durable for at least 6 months.
92 KCNMB1 cDna transfer was also shown to enhance erectile function in rats with stZ-induced diabetes up to 4 months after treatment. 93 the first human trial of gene transfer for the treatment of eD used plasmid bound KCNMB1 cDna administered by corporal injection. the human maxiK gene was successfully transferred to 6 men with eD and the plasmid was not detected in the participant's semen. Histopathological and blood chemistry results were within normal limits and no serious adverse events were reported that could be attributed to the therapy. statistically significant benefit was seen in patients that received the two highest doses of KCNMB1 cDna and this was maintained for 24 weeks. 94 these encouraging results have unfortunately not been replicated in other centers nor have additional results from this trial been forthcoming.
Stem cell therapy
stem cells are pluripotent cells that can be derived from numerous sources within the body, such as embryonic tissue, skeletal muscle, bone marrow, and adipose tissue. the relative merits of these different cell types are determined primarily by any ethical issues pertaining to their use, specifically in the case of embryonic cells, and potential host morbidity for harvest of other stem cell types. stem cells are defined by their capacity to divide and differentiate into many adult tissue types in vitro, including endothelial cells and smooth muscle. in the study of human diseases, stem cells are induced along particular lineages before injection; this process theoretically enhances cellular differentiation along desirable pathways after injection. stem cells are thus an appealing option for tissue regenerative therapy for eD, and a number of studies have explored their use in animal models (table 5) .
embryonic stem cells have immense biological potential but ethical concerns have limited their utilization in medical research. embryonic stem cells, induced to differentiate along the neural cell line by BDnF, have been injected into the major pelvic ganglion or penis of cavernous nerve injured rats, with significant improvements in iCP at 3 month follow-up. nerve tissue seemed qualitatively superior in the treated animals; however, there was no significant difference in naDPH staining between groups, which suggests that the no producing capacity of these neurons was not significantly altered and that another mechanism might be responsible for the beneficial effects observed. 95 rat fetal brain stem cells injected into cavernous tissue are able to survive for up to 6 weeks, where they have the capacity to differentiate into penile smooth muscle cells. 96 similarly, when injected into corpus cavernosa of healthy 10 week old rats, human neural crest stem cells express markers of smooth muscle and vascular endothelial cells for up to 2 weeks, 97 suggesting the potential for treating eD. However, functional testing was not performed in these studies and the erection preserving capacity of these treatments remains unclear.
immortalized human fetal bone marrow msCs express endothelial and smooth muscle specific antigens 2 weeks after injection into the cavernosa of young healthy rats. 96 this suggests that msCs have the capacity to differ entiate into both endothelial-like and smooth muscle cells in vivo. 98 Functional testing was not performed in this study so it is unclear whether the observed effects are clinically meaningful. However, the results of a study that investigated the penile injection of nonautologous msC with and without concomitant adenovirus mediated enos gene transfer, revealed marked and significant improvements in functional erectile hemodynamics at 7 and 21 days after treatment, implying that combination therapy restores erectile capacity in this model system. 37 in a study that combined histological and functional assessment, rat skeletal muscle-derived stem cells implanted into the corpora cavernosa of 20 month old rats demonstrated the capacity to express smooth muscle markers and signifi cantly enhance iCP, 2 and 4 weeks after treatment. 99 adipose-derived stem cells (aDsCs) are vascular stem cells obtained from perivascular areas of adipose tissue. they can be harvested in large quantities with minimal subject morbidity and therefore might represent an ideal stem cell source. 100 in a pilot experiment, aDsC have been shown to improve erectile function after bilateral cavernous crush injury in a rat model of eD (t. F. lue, unpublished work). additional studies in our lab have supported the efficacy of aDsCs for the treatment of erectile impairment owing to diabetes or hyper cholesterolemia. rats treated with aDsCs manifest superior erectile hemodynamics, generally improved smooth muscle:collagen ratios, and superior staining for neuronal nos (diabetic rats only). 101, 102 Future directions animal studies have provided a wealth of information concerning the therapeutic potential of both gene and stem cell based therapies. However, the death of Jesse Gelsinger, who died during a clinical trial for gene therapy, in the late 1990s was a serious blow to gene therapy research. in light of this, public concerns regarding the risk of gene therapy and the necessity for tight safety regulation has seriously impaired further progress in this field. 103 significant safety and efficacy concerns persist for both modalities. the potential for viral induced inflammation or propagation of gene transfer to nontarget cells remains a problem with viral vectors. nonviral vectors rEViEWS are available but are generally less efficient at gene transfer. these significant safety concerns have contributed to slow translation of gene therapy techniques to human patients; to our knowledge there has been only one human clinical trial of gene therapy for eD.
stem cell therapy is a new technology and studies are relatively scant at this time. although stem cell therapies avoid some of the issues surrounding gene therapy, legitimate concerns regarding the long-term fate of stem cells persist. the potential for malignant degeneration of transplanted stem cells must be elucidated before human trials can proceed. Furthermore, the ideal stem cell source has yet to be determined. embryonic stem cells are difficult to obtain and pose serious ethical dilemmas. nonautologous adult stem cells could be utilized but carry the risk of disease transmission or immune rejection. autologous stem cells minimize both ethical and immunogenic concerns but carry the risk of harvest site morbidity. identification of a stem cell source that is abundant, renewable, and can be harvested with minimum risk will be very important in accelerating research in stem cell biology.
Despite numerous current limitations, both technologies have the capacity to revolutionize the care of patients with eD and are therefore of great interest to clinicians interested in sexual health. several investigators have studied modalities that combine both techniques; it is possible that a combination approach will be the most successful in future clinical trials. although widespread clinical application of these technologies is years away, it might be speculated that gene or stem cell therapy, or a combination of both, could someday play a very significant role in enhancing sexual health for men with eD and their partners. these regenerative modalities are likely to be of particular interest to patients who have experienced a physiological insult (such as diabetes or radical pelvic surgery) that results in significant tissue defects, such as changes in smooth muscle:collagen ratio or defects of the tunica albuginea. Gene and stem cell therapy might help restore the natural form and function of the penis in this type of patient.
Conclusions
Gene and stem cell therapies have the potential to treat the underlying causes of eD, which would be a paradigm shift from the treatment options currently available that focus on short-term potentiation of blood flow into the penis without addressing underlying tissue defects. Further research is required to accurately elucidate the efficacy of these modalities. more importantly, the longterm safety of both gene and stem cell therapy must be thoroughly investigated before large scale human studies can be considered. 
Review criteria
We searched the published English language literature between 1966 and 2009 on both gene therapy and stem cell therapy for the management of erectile dysfunction. We primarily searched PubMed with search terms including "erectile dysfunction", "stem cells", and "gene therapy". We chose to focus on recent publications (within the last 10 years) as older publications tended to contain preliminary results that have been more thoroughly or clearly defined in more recent studies. Relevant articles were identified and obtained in full text form. Information was critically reviewed and synthesized.
Reference lists for several of the manuscripts identified via the search were reviewed and additional relevant citations were obtained from these.
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